Salesforce To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?

Amneal Pharmaceuticals shares surged 8.6% following completion of its Kashiv BioSciences acquisition, creating an integrated biosimilars platform. However, consensus EPS estimates were revised 23.1% lower over the past month, which could limit future gains. Ionis Pharmaceuticals declined 5.1% with unchanged negative EPS expectations.

Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.

Keybanc Maintains Overweight on AppFolio, Raises Price Target to $280

Keybanc analyst Jason Celino maintains AppFolio (NASDAQ:APPF) with a Overweight and raises the price target from $255 to $280.

Shares of software companies are trading higher after AI executives from firms including Anthropic, OpenAI and SpaceXAI signaled that the industry's growth may have to be slowed, which may limit threats to software vendors.

Ciena’s 2029 Outlook Draws Positive Analyst Reactions

Ciena 2029 Outlook targets 30% revenue CAGR, higher margins and stronger cash flow as Wall Street updates price targets.

Corning Rides on Expanding Partner Base: Will it Boost Prospects?

Corning Incorporated has significantly expanded its AI infrastructure business through multibillion-dollar agreements with Meta, Amazon, NVIDIA, and Verizon. The company will increase U.S. optical-connectivity capacity tenfold and expand fiber production by over 50% to support AI data center expansion. However, growth remains dependent on the pace of AI infrastructure investment and customer deployment timing.